IFG
KYMR icon

Independent Financial Group’s Kymera Therapeutics KYMR Stock Holding History

Independent Financial Group’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-8,182
Closed -$204K – 864
2022
Q4 		$204K Sell
8,182
-11,623
-59% -$310K 0.02% 712
2022
Q3 		$431K Buy
+19,805
New +$522K 0.04% 428

Other funds holding KYMR

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Independent Financial Group's KYMR Position: Q1 2023 in Review

Independent Financial Group sold out of Kymera Therapeutics (KYMR) in Q1 2023, closing a stake of 8,182 shares — an estimated $204K sold.

Independent Financial Group first reported a position in KYMR in Q3 2022 and held it in 2 quarters. The position peaked at $431K in Q3 2022. 127 funds tracked by Wall St. Rank hold KYMR as of Q1 2023.

  • Independent Financial Group reported no remaining Kymera Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Independent Financial Group sold 8,182 Kymera Therapeutics shares in Q1 2023, an estimated $204K.
  • Independent Financial Group first reported a position in Kymera Therapeutics in Q3 2022 and held it in 2 quarters.
  • Independent Financial Group's Kymera Therapeutics position peaked at $431K in Q3 2022.
  • 127 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2023.

Based on Independent Financial Group's 13F filing for Q1 2023, filed 12 Jun 2026.